Psilocybin-assisted therapy has hit a milestone as clinical trial results show potential benefits for Generalized Anxiety Disorder (GAD.)
With variable symptoms, the condition typically involves a person suffering from excessive anxiety and worry for over six months, potentially causing significant distress and impairment in social, occupational or other areas of functioning. A relatively common disorder, successful treatment of GAD remains inadequate, bringing on side effects and high costs.
The new topline clinical outcomes correspond to a Phase 2 study assessing psilocybin therapy's potential for treatment of Generalized Anxiety Disorder (GAD), conducted by clinical-stage cannabinoid and psychedelics biotech company...
Login or create a forever free account to read this news
Sign up/Log in